Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive women with HIV-1 infection (ARIA study): subgroup analyses

被引：0

作者：

Johnson, Margaret ^{[1
]}

Gatey, Caroline ^{[2
]}

Manosuthi, Weeraweet ^{[3
]}

Lazzarin, Adriano ^{[4
]}

Podzamczer, Daniel ^{[5
]}

Man, Choy ^{[6
]}

Aylott, Alicia ^{[7
]}

Buchanan, Annie ^{[6
]}

Wynne, Brian ^{[8
]}

Vavro, Cindy ^{[9
]}

Aboud, Michael ^{[10
]}

Smith, Kim ^{[11
]}

机构：

[1] Royal Free Hosp, Ctr HIV Med, London, England

[2] Hop St Louis, Serv Malad Infect & Trop, Paris, France

[3] Bamrasnaradura Inst, Dept Med, Nonthaburi, Thailand

[4] IRCCS Osped San Raffaele, Dipartimento Malattie Infett, Milan, Italy

[5] Ciudad Sanitaria & Univ Bellvitge, HIV Unit, Infect Dis Serv, Barcelona, Spain

[6] ViiV Healthcare, Clin Sci, Durham, NC USA

[7] GlaxoSmithKline, Clin Stat, London, England

[8] ViiV Healthcare, Clin Sci, Collegeville, PA USA

[9] ViiV Healthcare, Clin Virol, Durham, NC USA

[10] ViiV Healthcare, Global Med Sci, London, England

[11] ViiV Healthcare, Global Med Strategy, Durham, NC USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2016年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P035

引用

页数：2

共 7 条

[1] Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatmentnai naive women with HIV-1 infection (ARIA Study)
Orrell, C.
Hagins, D.
Belonosova, E.
Porteiro, N.
Walmsley, S.
Falco, V.
Man, C.
Aylott, A.
Buchanan, A.
Wynne, B.
Vavro, C.
Aboud, M.
Smith, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[2] Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection-48-week results from the GEMINI studies
Cahn, P.
Sierra Madero, J.
Arribas, J.
Antinori, A.
Ortiz, R.
Clarke, A.
Hung, C. -C.
Rockstroh, J.
Girard, P. -M.
Man, C.
Sievers, J.
Currie, A.
Underwood, M.
Tenorio, A.
Pappa, K.
Wynne, B.
Gartland, M.
Aboud, M.
Smith, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 156 - 156
[3] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
Orrell, Catherine
Hagins, Debbie P.
Belonosova, Elena
Porteiro, Norma
Walmsley, Sharon
Falco, Vicenc
Man, Choy Y.
Aylott, Alicia
Buchanan, Ann M.
Wynne, Brian
Vavro, Cindy
Aboud, Michael
Smith, Kimberly Y.
LANCET HIV, 2017, 4 (12): : E536 - E546
[4] Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG plus TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies
Orkin, C.
Porteiro, N.
Berhe, M.
Dretler, R.
Viciana, P.
Tseng, Y.
Oprea, C.
Johnson, M.
Kulagin, V.
Man, C.
Sievers, J.
Currie, A.
Underwood, M.
Tenorio, A.
Pappa, K.
Wynne, B.
Aboud, M.
Smith, K.
Gartland, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[5] Simplification to abacavir/lamivudine (ABC/3TC) + atazanavir (ATV) from tenofovir/emtricitabine (TDF/FTC) plus ATV/ritonavir (r) maintains viral suppression and improves bone biomarkers: 48 weeks ASSURE study results.
Wohl, David A.
Bhatti, Laveeza
Small, Catherine B.
Edelstein, Howard E.
Zhao, Henry
Margolis, David A.
Ross, Lisa L.
Shaefer, Mark S.
PHARMACOTHERAPY, 2013, 33 (10): : E211 - E212
[6] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study (vol 4, pg e546, 2017)
Orrell, C.
Hagins, D. P.
Belonosova, E.
LANCET HIV, 2017, 4 (12): : E535 - E535
[7] Comparison of efficacy and safety of a switch to fixed-dose combination FTC/TDF-TAF/RPV versus fixed-dose combination 3TC/ABC/DTG in HIV-1-infected, treatment experienced and virologically suppressed patients: a cohort study
Lagi, F.
Kiros, S. T.
Botta, A.
Meli, M.
Borchi, B.
Bartoloni, A.
Sterrantino, G.
HIV MEDICINE, 2019, 20 : 83 - 83

← 1 →